Suraxavir marboxil (GP681) is an orally available prodrug that is converted in vivo to the active metabolite GP1707D07, a PA-targeting antiviral against influenza. Because GP1707D07 is primarily ...
Scientists explored selectively blocking the CYP3A4 protein responsible for breaking down large swaths of approved drugs, providing a way to improve drug efficacy. Scientists at St. Jude Children's ...
PRINCETON, N.J.--(BUSINESS WIRE)-- Bristol Myers Squibb (BMY) (NYSE: BMY) today announced the Phase 3 ODYSSEY-HCM trial evaluating Camzyos (mavacamten) for the treatment of adult patients with ...
Am J Health Syst Pharm. 2006;63(23):2340-2348. MDR1 (ABCB1) T-129C, C1236T, G2677(T,A), C3435T No difference observed for cyclosporine and any CYP3A5 polymorphism Wild-type carriers of MDR1 (ABCB1) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results